SK15902000A3 - 10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie - Google Patents

10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie Download PDF

Info

Publication number: SK15902000A3
Authority: SK; Slovakia
Prior art keywords: paroxetine; camphorsulfonate; solution; treatment; salt
Prior art date: 1998-04-25

Application number

SK1590-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Michael Urquhart

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-25

Filing date

1999-04-23

Publication date

2001-05-10

1999-04-23 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-05-10 Publication of SK15902000A3 publication Critical patent/SK15902000A3/sk

Links

AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 34
229960002296 paroxetine Drugs 0.000 title claims abstract description 33
238000011282 treatment Methods 0.000 title claims abstract description 12
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 33
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 title claims description 18
239000012458 free base Substances 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
239000007787 solid Substances 0.000 claims description 8
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 6
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
238000002425 crystallisation Methods 0.000 claims description 3
230000008025 crystallization Effects 0.000 claims description 3
238000001953 recrystallisation Methods 0.000 claims description 3
208000007848 Alcoholism Diseases 0.000 claims description 2
208000032841 Bulimia Diseases 0.000 claims description 2
206010006550 Bulimia nervosa Diseases 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
208000019695 Migraine disease Diseases 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
206010041250 Social phobia Diseases 0.000 claims description 2
230000032683 aging Effects 0.000 claims description 2
201000007930 alcohol dependence Diseases 0.000 claims description 2
208000022531 anorexia Diseases 0.000 claims description 2
206010061428 decreased appetite Diseases 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
239000000155 melt Substances 0.000 claims description 2
206010027599 migraine Diseases 0.000 claims description 2
235000020824 obesity Nutrition 0.000 claims description 2
208000019906 panic disease Diseases 0.000 claims description 2
238000001556 precipitation Methods 0.000 claims description 2
238000007711 solidification Methods 0.000 claims description 2
230000008023 solidification Effects 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
208000002271 trichotillomania Diseases 0.000 claims description 2
238000001291 vacuum drying Methods 0.000 claims description 2
208000017667 Chronic Disease Diseases 0.000 claims 1
-1 Paroxetine 10-camphorsulfonates Chemical class 0.000 abstract description 2
208000015114 central nervous system disease Diseases 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
150000003839 salts Chemical class 0.000 description 18
239000002904 solvent Substances 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000002585 base Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229940079832 sodium starch glycolate Drugs 0.000 description 4
239000008109 sodium starch glycolate Substances 0.000 description 4
229920003109 sodium starch glycolate Polymers 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
238000001665 trituration Methods 0.000 description 3
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000000643 oven drying Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK1590-2000A 1998-04-25 1999-04-23 10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie SK15902000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9808894.1A GB9808894D0 (en)	1998-04-25	1998-04-25	Novel compound
PCT/GB1999/001246 WO1999055699A1 (en)	1998-04-25	1999-04-23	Paroxetine 10-camphorsulfonate for treatment of cns disorders

Publications (1)

Publication Number	Publication Date
SK15902000A3 true SK15902000A3 (sk)	2001-05-10

Family

ID=10831007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1590-2000A SK15902000A3 (sk)	1998-04-25	1999-04-23	10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie

Country Status (18)

Country	Link
EP (1)	EP1076659A1 (pt)
JP (1)	JP2002513020A (pt)
KR (1)	KR20010042929A (pt)
CN (1)	CN1306530A (pt)
AP (1)	AP2000001958A0 (pt)
AU (1)	AU3618699A (pt)
BG (1)	BG104973A (pt)
BR (1)	BR9909878A (pt)
CA (1)	CA2329913A1 (pt)
EA (1)	EA200001105A1 (pt)
GB (1)	GB9808894D0 (pt)
HU (1)	HUP0102298A2 (pt)
IL (1)	IL139018A0 (pt)
NO (1)	NO20005351D0 (pt)
PL (1)	PL343596A1 (pt)
SK (1)	SK15902000A3 (pt)
TR (1)	TR200003083T2 (pt)
WO (1)	WO1999055699A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100672184B1 (ko)	2004-09-21	2007-01-19	주식회사종근당	파록세틴의 콜린산 또는 콜린산 유도체 염
CN104402708A (zh) *	2014-12-07	2015-03-11	河南领先科技药业有限公司	一种樟脑酸钠的生产方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8430581D0 (en) *	1984-12-04	1985-01-09	Ferrosan As	Treatment
ES2058061T3 (es) *	1985-10-25	1994-11-01	Beecham Group Plc	Derivado de piperidina, su preparacion y su uso como medicamento.
HU221921B1 (hu) *	1996-07-08	2003-02-28	Richter Gedeon Vegyészeti Gyár Rt.	N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására

1998
- 1998-04-25 GB GBGB9808894.1A patent/GB9808894D0/en not_active Ceased
1999
- 1999-04-23 CA CA002329913A patent/CA2329913A1/en not_active Abandoned
- 1999-04-23 BR BR9909878-4A patent/BR9909878A/pt not_active Application Discontinuation
- 1999-04-23 JP JP2000545859A patent/JP2002513020A/ja active Pending
- 1999-04-23 AP APAP/P/2000/001958A patent/AP2000001958A0/en unknown
- 1999-04-23 HU HU0102298A patent/HUP0102298A2/hu unknown
- 1999-04-23 IL IL13901899A patent/IL139018A0/xx unknown
- 1999-04-23 CN CN99807798A patent/CN1306530A/zh active Pending
- 1999-04-23 PL PL99343596A patent/PL343596A1/xx not_active Application Discontinuation
- 1999-04-23 EA EA200001105A patent/EA200001105A1/ru unknown
- 1999-04-23 EP EP99918153A patent/EP1076659A1/en not_active Withdrawn
- 1999-04-23 SK SK1590-2000A patent/SK15902000A3/sk unknown
- 1999-04-23 KR KR1020007011750A patent/KR20010042929A/ko not_active Withdrawn
- 1999-04-23 WO PCT/GB1999/001246 patent/WO1999055699A1/en not_active Ceased
- 1999-04-23 TR TR2000/03083T patent/TR200003083T2/xx unknown
- 1999-04-23 AU AU36186/99A patent/AU3618699A/en not_active Abandoned
2000
- 2000-10-24 NO NO20005351A patent/NO20005351D0/no not_active Application Discontinuation
- 2000-11-21 BG BG104973A patent/BG104973A/bg unknown

Also Published As

Publication number	Publication date
JP2002513020A (ja)	2002-05-08
HUP0102298A2 (hu)	2002-05-29
BG104973A (bg)	2001-09-28
NO20005351L (no)	2000-10-24
IL139018A0 (en)	2001-11-25
NO20005351D0 (no)	2000-10-24
PL343596A1 (en)	2001-08-27
AP2000001958A0 (en)	2000-12-31
WO1999055699A1 (en)	1999-11-04
AU3618699A (en)	1999-11-16
TR200003083T2 (tr)	2001-02-21
CN1306530A (zh)	2001-08-01
BR9909878A (pt)	2000-12-26
CA2329913A1 (en)	1999-11-04
EA200001105A1 (ru)	2001-04-23
GB9808894D0 (en)	1998-06-24
KR20010042929A (ko)	2001-05-25
EP1076659A1 (en)	2001-02-21

Publication	Publication Date	Title
DE69704679T2 (de)	2001-09-13	4-phenylpiperidin-derivate
US20040242506A1 (en)	2004-12-02	Paroxetine glycyrrhizinate
SK20262000A3 (sk)	2001-07-10	Metánsulfonát paroxetínu v kryštalickej forme, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
JP4287752B2 (ja)	2009-07-01	アムロジピンニコチネート及びその製造方法
SK11812000A3 (sk)	2001-08-06	Soli paroxetínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
SK15032000A3 (sk)	2001-04-09	Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
SK15902000A3 (sk)	2001-05-10	10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie
KR20060080899A (ko)	2006-07-11	시부트라민의 무기산염
SK15912000A3 (sk)	2001-04-09	Askorbát paroxetínu, spôsob jeho výroby a jeho použitie
MXPA00010435A (en)	2001-07-31	Paroxetine 10-camphorsulfonate for treatment of cns disorders
US20040143120A1 (en)	2004-07-22	Paroxetine maleate
MXPA00010439A (en)	2001-07-31	Paroxetine ascorbate
AU2001100435A4 (en)	2001-11-01	Amlodipine fumarate
MXPA00009884A (en)	2001-12-13	Paroxetine maleate
CZ20003942A3 (cs)	2001-05-16	Askorbat paroxetinu
CZ20003941A3 (cs)	2001-05-16	10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému
CZ20002845A3 (cs)	2001-01-17	Soli paroxetinu
CZ20003722A3 (cs)	2001-04-11	Maleat paroxetinu
AU2528899A (en)	1999-08-23	Salts of paroxetine
MXPA00007719A (en)	2001-07-09	Salts of paroxetine